Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Gastric Adenocarcinoma 2Advanced Gastric Cancer 2Thymic epithelial tumor 1Solid Tumor 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neuroendocrine Tumors 1Locally Advanced Gastric Cancer 1Liver Neoplasms 1Liposarcoma 1HR+/HER2-breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 1apatinib 1Surveys and Questionnaires 1Radiomics 1Engineering 1Cisplatin 1Carboplatin 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neuroendocrine Tumors × apatinib × Clear all
NCT06764368 2025-01-08

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

Beijing Chest Hospital

Phase 2 Not yet recruiting
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡